Clinical Trials Browser

Phase 2/3 × Skin Neoplasms × pembrolizumab × Clear all

NCT06295809 2025-12-09

INTerpath-007

Phase 2/3 Active not recruiting

Carcinoma, Squamous Cell, Skin Neoplasms

NCT06947928 2025-10-14

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

Phase 2/3 Recruiting

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell